CTIC News 2.81 07/01/2014 04:40:49 Cell Therapeutics (CTIC)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cell Therapeutics (CTIC) 2.81 $CTIC

CTI BioPharma Completes Recruitment in PERSIST-1 Pivotal Phase 3 Trial of Pacritinib for Patients with Myelofibrosis
PR Newswire - Tue Jul 01, 12:30AM CDT
CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that it has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor that is being evaluated for the treatment of myelofibrosis. Under the development and commercialization agreement for pacritinib with Baxter International, Inc. (Baxter), CTI expects to receive a $20 million development milestone payment in connection with the first treatment dosing of the last patient enrolled in PERSIST-1. CTI expects to achieve this milestone and receive payment by mid-third quarter 2014.

Insider Trading Alert - FII, RP And CTIC Traded By Insiders
at The Street - Mon Jun 30, 9:30AM CDT
Stocks with insider trader activity include FII, RP and CTIC

Biotech Stocks on the Move -- Research on CTI BioPharma, BioMarin Pharma, Vertex Pharma, and Northwest Biotherapeutics
PR Newswire - Fri Jun 27, 6:00AM CDT
On Thursday, June 26, 2014, the NASDAQ Composite ended at 4,379.05, down 0.02%, the Dow Jones Industrial Average declined 0.13%, to finish the day at 16,846.13, and the S&P 500 closed at 1,957.22, down 0.12%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 708.54, up 0.06%, with the index also advancing 5.43% in the previous three months. Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corp. (NASDAQ: CTIC), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and Northwest Biotherapeutics Inc. (NASDAQ: NWBO). Free technical research on CTIC, BMRN, VRTX and NWBO can be downloaded upon signing up at:

Approvals, Agreements, Name Change, and Partnerships - Analyst Notes on Johnson & Johnson, Furiex Pharmaceuticals, Select Medical, CTI and Hill-Rom
PR Newswire - Fri Jun 13, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), Select Medical Holdings Corporation (NYSE: SEM), CTI BioPharma Corp. (NASDAQ: CTIC) and Hill-Rom Holdings, Inc. (NYSE: HRC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3701-100free.

CTI Announces United Kingdom National Cancer Research Institute AML Cooperative Group Initiates Randomized Phase 2 Trial Evaluating Tosedostat plus Cytarabine for Older Patients with AML or High-Risk MDS
PR Newswire - Thu Jun 12, 12:30AM CDT
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of an international cooperative group Phase 2 clinical trial of tosedostat in combination with low-dose cytarabine in older patients with Acute Myeloid Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival. The trial is being conducted by the National Cancer Research Institute Haematological Oncology Study Group under the sponsorship of Cardiff University. The trial management group is led by Professor Alan K. Burnett, Head of Haematology in the Department of Medical Genetics, Haematology and Pathology at the School of Medicine at Cardiff University. Chroma Therapeutics Ltd., from whom CTI licensed tosedostat, is facilitating drug supply for the trial.

Insider Trading Alert - MWE, CPT And CTIC Traded By Insiders
at The Street - Mon Jun 09, 9:16AM CDT
Stocks with insider trader activity include MWE, CPT and CTIC

Cell Therapeutics reports rebranding of its corporate name
M2 - Fri May 30, 3:06AM CDT
Biopharmaceutical company Cell Therapeutics (NASDAQ:CTIC)(MTA:CTIC) announced on Friday a change in its corporate name to CTI BioPharma with immediate effect.

Cell Therapeutics, Inc. Announces Change of Name to CTI BioPharma Corp.
PR Newswire - Fri May 30, 12:30AM CDT
Cell Therapeutics, Inc. (CTI or the Company) (NASDAQ and MTA: CTIC), a biopharmaceutical company focused on acquiring, developing and bringing to market novel targeted therapies for blood-related cancers, today announced that it will change its corporate name to CTI BioPharma Corp. effective May 30, 2014. The Company's common stock will continue to trade under its current ticker symbol: "CTIC."

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Cell Therapeutics, Inc. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Thu May 29, 11:52AM CDT
Levi & Korsinsky, LLP is investigating Cell Therapeutics, Inc. (NasdaqCM: CTIC) in connection with possible claims of breaches of fiduciary duty by certain members of the board of directors of the Company.

CollabRx's Mobile App Simplifies Cancer Treatment Options
ACCESSWIRE - Thu May 29, 9:46AM CDT
WHITEFISH, MT / May 29, 2014 / Treating cancer patients has become increasingly difficult given the condition's incredibly wide scope. For example, breast cancer can be treated in two very different ways depending on whether a patient is HER2 positive, triple negative, triple positive, or endocrine receptor positive. These types of tests and treatments are only increasing in scope as more genetic markers are discovered.

Cell Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference
PR Newswire - Thu May 29, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4 at 11:30 a.m. PDT/2:30 p.m. EDT/8:30 p.m. CEST in New York.

Top Gainers on the Move -- Research on Aeropostale, FirstEnergy, Cell Therapeutics, and Dyax
PR Newswire - Wed May 28, 4:00AM CDT
The US markets saw a positive sentiment on Tuesday, May 27, 2014, with the NASDAQ Composite closing at 4,237.07, up 1.22%, the Dow Jones Industrial Average ending the session at 16,675.50, up 0.42% and the S&P 500 edging 0.60% higher to finish the trading session at 1,911.91. The gains were broad based as nine out of ten sectors ended the session in positive. A number of stocks saw large movements, including Aeropostale Inc. (NYSE: ARO), FirstEnergy Corp. (NYSE: FE), Cell Therapeutics Inc. (NASDAQ: CTIC) and Dyax Corp. (NASDAQ: DYAX). Free technical research on ARO, FE, CTIC and DYAX can be downloaded upon signing up at:

Stock to Watch: Cell Therapeutics Up 7.0% (CTIC)
Comtex SmarTrend(R) - Tue May 27, 11:41AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 7.0% to $3.06 on 1.0x average daily volume. Cell Therapeutics has traded 2.6 million shares thus far today, vs. average volume of 2.5 million shares per day. The stock has outperformed the Dow (7.0% to the Dow's 0.3%) and outperformed the S&P 500 (7.0% to the S&P's 0.4%) during today's trading.

Why NTELOS, Cell Therapeutics, and Sanchez Energy Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu May 22, 4:28PM CDT
When things are going right, not even mixed economic data can push the broad-based S&P 500 lower. The headline story that I would have expected to pressure the S&P 500 throughout the day was the weekly initial jobless claims figure....

Why Cell Therapeutics (CTIC) Stock Is Spiking Today
at The Street - Thu May 22, 11:27AM CDT
Cell Therapeutics (CTIC) is rocketing up today after being initiated with a 'buy' rating by analysts at Ladenburg (LTS).

Stock to Watch: Cell Therapeutics Up 12.2% (CTIC)
Comtex SmarTrend(R) - Thu May 22, 10:10AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 12.2% to $2.85 on 1.0x average daily volume. Cell Therapeutics has traded 2.6 million shares thus far today, vs. average volume of 2.5 million shares per day. The stock has outperformed the Dow (12.2% to the Dow's 0.2%) and outperformed the S&P 500 (12.2% to the S&P's 0.3%) during today's trading.

Zack's Research Initiates Coverage on Theralase With a Price Target of $1.00
ACCESSWIRE - Tue May 20, 9:22AM CDT
Theralase Lights Up Cancer Therapeutics

Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Technical Coverage on Biotech Stocks -- Research on Celgene, Cell Therapeutics, Geron, and BioMarin Pharma
PR Newswire - Tue May 06, 8:15AM CDT
The trading session on Monday, May 05, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the day 0.19% higher at 1,884.66. The gains were broad based as eight out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day 0.56% higher at 672.57, and the index has gained 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Cell Therapeutics Inc. (NASDAQ: CTIC), Geron Corporation (NASDAQ: GERN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free technical research on CELG, CTIC, GERN and BMRN can be downloaded upon signing up at:
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Medtronic's Bold Move to Own Carotid Market Full-Scale

Updated Category News Views 64

When a giant like Medtronic makes a move, you can bet investors take notice, and this latest acquisition is no exception. They’re reaching into their deep pockets to acquire Contego Medical, a company shaking up the world of carotid artery disease treatments. It’s a tactical strike to solidify their leadership in cardiovascular solutions. Medtronic's Bet on Innovation...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 421

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 105

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 459

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Priceline's Cyber Week: A Pocket-Friendly Travel Bonanza

Updated Category News Views 88

Unpacking Priceline's Cyber Week Bonanza Alright, folks, grab your booking hats because Priceline is back with its annual Cyber Week extravaganza, aiming to give travelers a shot in the arm of savings just when inflation has everyone pinching pennies. From November 16 through December 2, Priceline rolls out the red carpet for vacation planners, offering eye-popping...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 34

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 81

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
HearUSA Expands Access with AI-Powered Hearing Aids

Updated Category News Views 61

AI Revolution in Hearing Care Look, the hearing aid industry isn't known for headlines that grab you by the throat, but HearUSA just tossed a proverbial grenade into the scene with Widex Allure AI RIC. This is more than a slight tweak in hearing tech—it's a game-changer. We're talking about on-demand AI noise management blended with Widex's renowned natural sound. It's...

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 29

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 33

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading

Top 5 Most Recently Viewed Articles

Bitcoin's Critical Moment: Navigating Possible Downtrends

Updated Category News Views 58

Understanding Bitcoin's Potential Death Cross There's a lot of chatter right now about a possible death cross for Bitcoin, which has fascinated traders and investors alike. This event happens when a short-term moving average, like the 50-day, dips below a long-term moving average, such as the 200-day. This intersection suggests a potential bearish trend in price movement....

Continue Reading
Calamos Enhances Investment Options with New ETF Offering

Updated Category News Views 175

Calamos Launches Innovative ETF for S&P 500 Investors The new Calamos S&P 500 Structured Alt Protection ETF offers an enticing proposition for investors seeking exposure to the S&P 500 while safeguarding against potential downturns. This ETF, identified as CPSF, aims to provide 100% downside protection over a one-year timeline, allowing investors to navigate market...

Continue Reading
Rising Global Defense Expenditure Transforms Drone Technologies

Updated Category News Views 273

Transforming Defense with Advanced Drone Solutions The military drone market is experiencing remarkable growth as governments around the world respond to rising geopolitical tensions. The increase in global defense budgets is fueling investment in unmanned aerial systems (UAS), propelling innovation and expansion in the sector. The Current State of the Military Drone...

Continue Reading
Soft N Dry Launches Innovative Diaper Connection Programme

Updated Category News Views 115

Enhancing Retail Connections for Sustainability Soft N Dry Diapers Corp. (NASDAQ: SDC) is taking a significant step in enhancing its relationships with retailers through the launch of its Retail Consumer Connection Programme (RCCP). The initiative is designed to give retailers the support they need to stock the groundbreaking TreeFree Diaper™, which is driving consumer...

Continue Reading
Understanding Truck Accident Settlements in Memphis

Updated Category News Views 27

Delving into Truck Accident Settlement Timelines Out there in Memphis, timing a truck accident settlement isn't exactly like clockwork work. When it comes to getting your compensation, the timeline varies as widely as a duck hunting trip—sometimes you come home with a basketful, sometimes it’s empty. It might be a quick couple of months or drag on past a year, and...

Continue Reading